Sanofi SNY and partner Regeneron REGN announced that the FDA has approved their blockbuster drug, Dupixent, for its sixth ...

The drug was administered twice-daily using a nebuliser as a chronic maintenance therapy for people with COPD in the ENHANCE ... must surely now be on the hit-list of potential takeover targets.

The list for the next round of medicines that ... reckons a chronic obstructive pulmonary disease (COPD) drug will be included – and is preparing to contribute to the process.

Regeneron and Sanofi shares edged higher Friday after their drug to treat chronic obstructive pulmonary disease (COPD) received approval from the Food and Drug Administration (FDA). The drug ...

GSK’s GSK phase III study evaluating its blockbuster drug Nucala (mepolizumab ... stage studies for COPD. GSK has a Zacks Rank #3 (Hold). You can see the complete list of today’s Zacks ...

using National Drug Codes for anticholinergics, beta-agonists, and combination medications, and number of days covered by ≥1 COPD medication divided by total number of days. Variables were ...

Patients with COPD often experience chronic cough, difficulty breathing, and reduced lung function. While the respiratory disease is not curable, it can be treated and managed with medications ...

and routinization of drug therapy are critical for optimal medication adherence in patients with COPD.

but the Food and Drug Administration’s approval of the drug for chronic obstructive pulmonary disease greatly expands its reach — and could give it an edge over rival treatments in development.

The medication adherence report scale (MARS ... A nutrition guide for patients with COPD was included as an ethically acceptable incentive to encourage patient response. The study received ...